Fecal Microbiota Transplantation for Chronic Kidney Disease: Formulation and In Vivo Studies

This study is about trying a new approach to fecal microbiota transplantation for chronic kidney disease (CKD). The main goal is to create a pharmaceutical formulation of fecal suspensions from healthy volunteers. This is important because it could potentially improve the treatment of CKD by modulating the intestinal microbiota, which may affect renal function and levels of uremic toxins. The study focuses on healthy volunteers who will donate their fecal samples for this purpose. The study begins with collecting fecal samples from healthy volunteers, after they have been screened and enrolled. The screening process involves two interviews and laboratory tests to ensure the donors are healthy and free from potentially transmittable diseases. Once the best product design is determined, a prototype will be produced. This prototype will then be tested on a CKD mouse model to evaluate its effects on renal function, uremic toxin levels, intestinal microbiota, and microbiota composition. The study aims to enroll 10 healthy volunteers according to the FMT01 protocol. The volunteers will be selected carefully to avoid any potential risks.